Bronchogen vs Melanotan 1
Side-by-side comparison of key properties, dosing, and research.
Anti-Aging & Longevity
BronchogenSkin & CosmeticSexual Health & Libido
Melanotan 1- Summary
- Bronchogen is a tetrapeptide bioregulator (Ala-Glu-Asp-Leu) developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. It is a tissue-specific bioregulator designed for the bronchi and lungs, promoting normalization of bronchial epithelial cell function. Research suggests benefits for respiratory health, protection against pulmonary aging, and support for bronchopulmonary conditions.
- Melanotan 1 (Afamelanotide) is a synthetic analog of α-MSH that selectively stimulates melanogenesis (tanning) through MC1R activation. It provides UV-independent skin pigmentation and is FDA/EMA-approved under the name SCENESSE for erythropoietic protoporphyria (EPP) and vitiligo.
- Half-Life
- Short (minutes to hours); bioregulator effects are gene-mediated and longer lasting
- ~40–60 minutes (free peptide); implant formulation (SCENESSE) releases over months
- Admin Route
- SubQ, Oral
- SubQ
- Research
- —
- —
- Typical Dose
- 10 mg per day
- 0.5–1 mg
- Frequency
- Daily for 10–30 days
- Daily until desired color achieved, then maintenance
- Key Benefits
- Tissue-specific support for bronchial and lung health
- Promotes normalization of bronchial epithelial cell function
- Potential benefits in chronic bronchitis and COPD support
- Anti-aging effects on pulmonary tissue
- May reduce frequency of respiratory infections
- Supports lung function preservation with aging
- Compatible with other Khavinson bioregulator peptides
- Induces skin pigmentation/tanning without UV exposure
- Provides photoprotection in photosensitivity conditions (EPP)
- FDA-approved for erythropoietic protoporphyria (SCENESSE)
- Approved in EU for EPP treatment
- Anti-inflammatory via MC1R
- Mild libido enhancement
- Potential skin cancer prevention through melanin protection
- Side Effects
- Generally well tolerated in research studies
- Mild local reactions at injection site (if injected)
- No significant systemic side effects reported at standard doses
- Nausea (especially at higher doses)
- Facial flushing
- Fatigue
- Injection site reactions
- +3 more
- Stacks With
- —
- —